Biosimilarity in Latin America
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 2
Abstract
The introduction of new legislation in Latin America for the approval of biosimilar products follows implementation of EU legislation in 2005 for biosimilars approval. The establishment of regulatory processes for these complex drugs will ensure that evidence of safety and efficacy is obtained before approval. Biosimilars are high on the health-policy agenda because they are less costly and potentially more accessible, and also because of the imminent expiration of a number of patents on biological products. Within individual Latin American countries, the regulatory processes and stages of implementation vary.
Authors and Affiliations
Chang Chiann, Leonardo de Souza Teixeira, Fabiana Fernandes de Santana e Silva Cardoso, Isabela da Costa César, Gerson Antônio Pianetti
Keywords
Related Articles
- EP ID EP355039
- DOI 10.5639/gabij.2013.0202.021
- Views 122
- Downloads 0
Maximizing quality in the manufacture of biologicals
Biological product quality is susceptible to unexpected manufacturing issues, and the resulting variation may impact the safety or efficacy of these medicines and increase risks to patients. These risks can be managed mo...
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...
Reference pricing systems in Europe: characteristics and consequences
Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview...
Perceptions of physicians from private medical centres in Malaysia about generic medicine usage: a qualitative study
Introduction: The healthcare sector is one of the most rapidly expanding and dynamic industries in the world. Pharmaceutical expenditure is now growing faster than other components of healthcare overheads. Globally, pres...
Biosimilar monoclonal antibodies – time for a regulatory rethink
The approval of biosimilars in the European Union (EU) is governed by the EU biosimilar framework released in 2004. But new arrivals on the biosimilar stage – monoclonal antibodies – are forcing regulatory authorities to...